Agenus Inc. (NASDAQ:AGEN – Get Free Report) has received an average rating of “Moderate Buy” from the six brokerages that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $24.50.
A number of research firms recently commented on AGEN. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective (down from $30.00) on shares of Agenus in a research note on Tuesday, August 11th. B. Riley Financial reissued a “buy” rating and issued a $14.00 target price (up from $8.00) on shares of Agenus in a research note on Thursday, July 30th. Rodman & Renshaw initiated coverage on shares of Agenus in a report on Monday, September 28th. They issued a “buy” rating and a $19.00 target price on the stock. Weiss Ratings upgraded shares of Agenus from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, October 8th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $40.00 price target on shares of Agenus in a research note on Monday, October 5th.
View Our Latest Research Report on AGEN
Agenus Stock Performance
Shares of NASDAQ:AGEN opened at $6.18 on Tuesday. The business’s fifty day moving average price is $7.73 and its two-hundred day moving average price is $5.44. The stock has a market cap of $279.09 million, a PE ratio of 2.40 and a beta of 1.31. Agenus has a one year low of $2.71 and a one year high of $10.31.
Agenus (NASDAQ:AGEN – Get Free Report) last released its quarterly earnings results on Friday, August 7th. The biotechnology company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.06). Agenus had a negative return on equity of 47.68% and a net margin of 69.33%. The company had revenue of $34.52 million for the quarter, compared to analysts’ expectations of $34.00 million. As a group, equities research analysts predict that Agenus will post -0.30 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Agenus
Several institutional investors and hedge funds have recently modified their holdings of AGEN. Everhart Financial Group Inc. purchased a new stake in Agenus in the 3rd quarter worth approximately $100,000. Globeflex Capital L P acquired a new position in Agenus in the 2nd quarter valued at $1,281,000. Bank of New York Mellon Corp purchased a new position in shares of Agenus during the 2nd quarter worth $311,000. Bank of America Corp DE lifted its stake in shares of Agenus by 796.7% during the 1st quarter. Bank of America Corp DE now owns 118,782 shares of the biotechnology company’s stock worth $397,000 after purchasing an additional 105,536 shares during the period. Finally, Redwood Family Wealth LLC acquired a new stake in shares of Agenus during the fourth quarter worth $44,000. Hedge funds and other institutional investors own 61.46% of the company’s stock.
Agenus Company Profile
Agenus Inc (NASDAQ: AGEN) is a biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research programs are designed to activate and strengthen the immune system’s ability to recognize and attack tumors, with an emphasis on therapies that may be used alone or in combination.
Agenus’ pipeline includes botensilimab, an investigational Fc-enhanced CTLA-4 antibody, and balstilimab, an investigational PD-1 inhibitor. The company has studied these therapies in combination across several solid-tumor indications, including colorectal cancer and other advanced cancers.
Featured Stories
- Five stocks we like better than Agenus
- Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves
- The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway
- Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants
- Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.
